For people with dMMR* endometrial cancer that has returned or spread outside the uterus (advanced) and after you have received chemotherapy containing platinum and your cancer cannot be treated by surgery or radiationJEMPERLI offers meaningful results

*dMMR stands for “mismatch repair deficiency.” It is an important biomarker in endometrial cancer that can help your doctor decide if JEMPERLI is right for you.

How JEMPERLI may help

Researchers studied how JEMPERLI works in 141 study participants with dMMR endometrial cancer that had spread (advanced) or returned. These people had previously received chemotherapy containing platinum that did not work or stopped working.

Many study participants receiving JEMPERLI alone had their tumors disappearor partially shrink

Response rates for JEMPERLI when given alone

45% of study participants had tumors DISAPPEAR OR PARTIALLY SHRINK (64 of 141 participants)

16% of study participants had tumors DISAPPEAR (22 of 141 participants)

30% of study participants had tumors PARTIALLY SHRINK (42 of 141 participants)

This does not always mean that the cancer has been cured.

Many participants in the study had a continued response with JEMPERLI

Person with lightbulb icon

86% of study participants who responded to treatment kept their response for 1 YEAR OR LONGER

Person with lightbulb icon

55% of study participants who responded to treatment kept their response for LONGER THAN 2 YEARS

In study participants with tumors that responded to treatment, the duration of their responses (DOR) ranged from 1.2+ to 52.8+ months with the median duration of responsenot reached. Follow-up for half of these study participants was at least 27.9 months.

Median (MEE-dee-un) duration of response is the amount of time until the cancer began growing or spreading again for half of the responding study participants.

+ means still responding at last follow-up.

You are not alone

Endometrial cancer statistics infographic

About 60,000 cases of endometrial cancer are diagnosed annually in the US

About 1 in 4 peoplepeople with endometrial cancer has cancer that has come back after treatment or has spread outside the uterus (advanced cancer)

Light bulb icon

Is JEMPERLI right for you?

If you were diagnosed with dMMR endometrial cancer that has spread outside the uterus (advanced) or your cancer has returned, ask your doctor if JEMPERLI may be right for you.

Learn About dMMR

Light bulb icon

What is JEMPERLI?

JEMPERLI is an immunotherapy. This means it is designed to work with the body’s immune system to help fight cancer.

Learn How It Works

Exclamation point in triangle icon

What are the side effects of JEMPERLI?

Certain side effects have been observed in people taking JEMPERLI. While everyone’s treatment experience is different, knowing what you may expect can help.

See Risks and Side Effects

Download icon

Resources for you

Knowledge is power. That's why we're committed to providing you with educational resources to help you stay informed along your treatment journey.

Go to Resources

Related FAQs

  • How many people participated in the clinical trial of JEMPERLI alone?

    The clinical trial that studied the effectiveness of JEMPERLI alone included 141 people. They had dMMR endometrial cancer that had returned or spread; they had also previously received chemotherapy containing platinum that did not work or stopped working.

    The clinical trial also studied the risks and side effects of JEMPERLI alone in 150 people who had dMMR endometrial cancer.

  • What does dMMR mean?

    dMMR stands for "mismatch repair deficiency." It is an important biomarker in endometrial cancer that can help your doctor decide if JEMPERLI is appropriate for you.

  • Is advanced or returned endometrial cancer common?

    About 1 in 4 people with endometrial cancer has cancer that has spread outside the uterus (advanced) or has returned.